CoChat

Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics

The DOI matches its Crossref record, with a small difference in title or year; 199 of the 199 references it cites were found in a registry or an index.

Abstract

Drug-induced vascular injury (DIVI) is a recurrent challenge in the development of novel pharmaceutical agents. Although DIVI in laboratory animal species has been well characterized for vasoactive small molecules, there is little available information regarding DIVI associated with biotherapeutics such as peptides/proteins or antibodies. Because of the uncertainty about whether DIVI in preclinical studies is predictive of effects in humans and the lack of robust biomarkers of DIVI, preclinical DIVI findings can cause considerable delays in or even halt development of promising new drugs. This review discusses standard terminology, characteristics, and mechanisms of DIVI associated with biotherapeutics. Guidance and points to consider for the toxicologist and pathologist facing preclinical cases of biotherapeutic-related DIVI are outlined, and examples of regulatory feedback for each of the mechanistic types of DIVI are included to provide insight into risk assessment.

Overview

Integrity signals

Registry

Crossref · 10.1177/0192623315570340

Cites

199 of 199 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 199 references

Research works printed but not linked: 34

  1. Albassam M. A., 1993, Lab Anim Sci, 43, 628
  2. Alexander N. J., 1985, Lab Anim Sci, 35, 465
  3. Alpers C. E., 2009, Pathologic Basis of Disease, Professional Edition, 930
  4. Anderson T. D., 1989, Lab Invest, 60, 331
  5. Barron K., 1988, J Rheumatol, 15, 1243
  6. Blann A. D., 2005, Thromb Haemost, 3, 228
  7. Bugelski P. J., 2004, Curr Opin Mol Ther, 6, 10
  8. Casselman B. L., 1995, J Lab Clin Med, 126, 495
  9. Cines D. B., 1998, Blood, 91, 3527
  10. Conn D. L., 1976, Mayo Clin Proc, 56, 511
  11. Daguès N., 2007, Toxicol Sci, 107, 298
  12. Day C. J., 2003, Clin Exp Rheumatol, 21, S35
  13. Dhir V., 2012, J Immunol, 9, 34
  14. Enerson B., 2010, Toxicologist, 114, 7
  15. Erdbruegger U., Dhaygude A., Woywodt A. (2011). Markers of Vascular Damage and Repair, Advances in the Etiology, Pathogenesis and Pathology of Vasculitis (Amezcua-Guerra Luis M.Dr, ed.), pp. 179–94. Elsevier, ISBN: 978-953-307-651-5.
  16. Frazier K. S., 2014, Toxicol Pathol
  17. Frazier K. S., 2013, Toxicologic Pathology: Preclinical Safety Assessment, 426
  18. Galaria N. A., 2000, J Rheumatol, 27, 2041
  19. Gimbrone M. A., 1997, J Clin Invest, 100, S61
  20. Jeppesen G., 2014, Toxicol Pathol, 42
  21. Jennette J. C., 1995, Ann Acad Med Singapore, 24, 248
  22. Johansson S., 1981, Acta Path Microbial Scand Sect A, 89, 185
  23. Kerns W. D., 1989, Am J Pathol, 135, 339
  24. Kumar V., 2010, Robbins and Cotran Pathologic Basis of Diseaes, 183
  25. 10.1002/1529-0131(199904)42:3<561::aid-anr22>3.0.co;2-x · doi:10.1002/1529-0131(199904)42:3<561::aid-anr22>3.0.co;2-x
  26. Mannik M., 1987, J Rheumatol, 14, 35
  27. Moyer C. F., 1987, Am J Pathol, 127, 229
  28. Radic M., 2012, Neth J Med, 70, 12
  29. Sivakumar P. V., 2013, Comp Med, 63, 13
  30. Stewart R. J., 1994, Kidney Int Suppl, 45, S37
  31. Stills H. F., 1983, Am J Pathol, 113, 222
  32. Wu H., 2007, Clin Lab, 53, 285
  33. Yuhas E. M., 1985, Am J Pathol, 119, 83
  34. Zhang J., 2002, Toxicologist, 66, 15

Cited by

See all 36

Metadata

Authors
Frazier, K. S., Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C., Scicchitano, M. S., Weaver, J. L., & Zabka, T. S.
Affiliations
  • GlaxoSmithKline (United States) (US)
  • Ionis Pharmaceuticals (United States) (US)
  • WIL Research Europe, Saint-Germain-Nuelles, France
  • MedImmune, Cambridge, UK
  • Pfizer (United States) (US)
  • Raritan, Somerset, New Jersey, USA
  • United States Food and Drug Administration (US)
  • Genentech (US)
Corresponding author
Frazier, Kendall S.
Venue
Toxicologic Pathology
Published
2015-02-26
Volume
43
Issue
7
Pages
915-934
ISSN
  • 0192-6233 (ISSN-L)
  • 1533-1601
OpenAlex
W2097919342
Cited by
35
References
199
Citations by year
2026: 1 · 2025: 4 · 2024: 1 · 2022: 1 · 2021: 5 · 2020: 5 · 2019: 7 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 1
FWCI
0.34
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Toxicologic Pathology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
  • Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
Keywords
drug-induced vascular injury, biologic therapy, immunoglobulins, peptides, preclinical toxicology, regulatory toxicology, biomarkers, risk assessment, drug development, feedback regulation
MeSH terms
Animals, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Vascular System Injuries, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics. https://app.cochat.ai/papers/10.1177/0192623315570340
The paper
Frazier, K. S., Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C., Scicchitano, M. S., Weaver, J. L., & Zabka, T. S. (2015). Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics. Toxicologic Pathology. https://doi.org/10.1177/0192623315570340

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.